The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Opdivo, part of a new class of medicines designed to use the body's ... Reuters, 1 month ago
Roche cancer drug taking bite out of Bristol's Opdivo - Reuters, 1 month ago
Merck, Bristol-Myers agree to settle Keytruda patent suit - Reuters, 2 months ago
By Martinne Geller (Reuters) - Reckitt Benckiser Group Plc is in advanced talks to buy Mead Johnson Nutrition Co in a $16.7 billion deal that would take the British consumer goods maker into the baby formula market and boost its business outside of Europe.Sify, 1 month ago
on your WebpageAdd Widget >Get your members hooked!